In routine clinical practice, rivaroxaban demonstrates high 2-year persistence (90.6%) and low rates of major cardiac events in patients with nonvalvular atrial fibrillation.
Supports real-world rivaroxaban persistence in AF; leaves open randomized confirmation of long-term net benefit.
AIM: To evaluate medication persistence and outcomes in patients with atrial fibrillation after 2 years of treatment with rivaroxaban in routine practice. METHODS: Retrospective study of atrial fibrillation patients in whom rivaroxaban was prescribed during the first quarter of 2014 in the healthcare area of Costa del Sol (Málaga). RESULTS: -VASc 3.6 ± 1.3; HAS-BLED 1.3 ± 0.6) were included. A total of 96.3 and 90.6% of patients remained on rivaroxaban therapy after 1 and 2 years of treatment, respectively. During this period, stroke, net clinical benefit outcome (thromboembolic events, myocardial infarction, cardiovascular death and major bleeding) and cardiovascular death occurred in 3.6, 5.4 and 1.8% of patients, respectively. CONCLUSION: In routine practice, medication persistence with rivaroxaban was high. Rates of major cardiac events were low.
No takes yet. Share an insight, caveat, or question.
Cabeza et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: